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Abstract 
Background: An estimated 8–30 % of people living with HIV (PLWH) have depressive disorders (DD) in sub-Saharan 
Africa. Of these, the majority are untreated in most of HIV care services. There is evidence from low- and middle- 
income countries of the effectiveness of both psychological treatments and antidepressant medication for the 
treatment of DD among PLWH, but no evidence on how these can be integrated into routine HIV care. This protocol 
describes a cluster-randomised trial to evaluate the effectiveness and cost-effectiveness of the HIV + D model for the 
integration of a collaborative stepped care intervention for DD into routine HIV care, which we have developed and 
piloted in Uganda.
Methods: Forty public health care facilities that provide HIV care in Kalungu, Masaka and Wakiso Districts will be 
randomly selected to participate in the trial. Each facility will recruit 10–30 eligible PLWH with DD and the total sample 
size will be 1200. The clusters will be randomised 1:1 to receive Enhanced Usual Care alone (EUC, i.e. HIV clinicians 
trained in Mental Health Gap Action Programme including guidelines on when and where to refer patients for psy-
chiatric care) or EUC plus HIV + D (psychoeducation, Behavioural Activation, antidepressant medication and referral to 
a supervising mental health worker, delivered in a collaborative care stepwise approach). Eligibility criteria are PLWH 
attending the clinic, aged ≥ 18 years who screen positive on a depression screening questionnaire (Patient Health 
Questionnaire, PHQ-9 ≥ 10). The primary outcome is the mean depressive disorder symptom severity scores (assessed 
using the PHQ-9) at 3 months’ post-randomisation, with secondary mental health, disability, HIV and economic 
outcomes measured at 3 and 12 months. The cost-effectiveness of EUC with HIV + D will be assessed from both the 
health system and the societal perspectives by collecting health system, patient and productivity costs and mean 
DD severity scores at 3 months, additional to health and non-health related quality of life measures (EQ-5D-5 L and 
OxCAP-MH).
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Background
An estimated 25 million Africans are living with HIV, and 
of these, approximately 8–30 % have depressive disor-
ders (DD) [1–5]. DD in persons living with HIV (PLWH) 
not only impair quality of life [6], but are associated 
with other adverse outcomes such as rapid HIV disease 
progression including mortality [7, 8], poor adherence 
to HIV treatment [3, 9, 10], risky sexual behaviour [10, 
11] and increased utilisation of health facilities [3, 10]. 
Despite this, the majority of HIV care providers in sub-
Saharan Africa do not routinely provide mental health 
services [5]. This represents a significant gap as antiretro-
viral therapy (ART) is scaled-up and HIV transitions into 
a chronic disease [12]. In contrast, HIV services in some 
high income countries have successfully integrated men-
tal health care into general HIV care services [13].
The Uganda National HIV and AIDS Strategic Plan 
(2015–2020) calls for the integration of care for mental 
disorders and other chronic conditions in HIV care ser-
vices [14]. To operationalise this recommendation, the 
Ministry of Health released guidelines for HIV treat-
ment [15] calling for the assessment and management of 
depression as an integral part of HIV care programs. The 
aim of the proposed study is to evaluate the effectiveness 
of the HIV + D intervention on DD, functional outcomes 
and its cost-effectiveness in routine HIV care in Uganda. 
The study is led by the Medical Research Council (MRC)/
Uganda Virus Research Institute (UVRI) & London 
School of Hygiene and Tropical Medicine (LSHTM) 
Uganda Research Unit in partnership with the Ministry 
of Health.
Currently in Uganda, there is no mental health care in 
HIV care services provided at public health care facili-
ties (PHCFs) in the country. Challenges to such provi-
sion include: (a) low demand for formal mental health 
services (most patients with mental health problems first 
seek care from traditional healers and/or faith healers 
before coming to formal mental health care services); (b) 
a severe shortage of mental health professionals (Uganda 
has only about 30 psychiatrists, the majority of whom 
work in the capital city of Kampala); (c) the reluctance 
of primary care providers to engage in mental health 
care (due to lack of training in mental health, apprecia-
tion of the value of mental health care and the time and 
resources due to competing demands) and (d) a severe 
shortage of primary care workers in most PHCFs (which 
typically have one clinician for 50–100 patients daily) [16, 
17].
Studies from low-and middle-income countries (LMIC) 
show effectiveness of psychological treatments and anti-
depressant medication for depressive and anxiety disor-
ders among PLWH in reducing mental health symptoms 
[18–20] and HIV disease progression [21]. However, a 
critical knowledge gap remains regarding how such treat-
ments can be integrated in routine HIV care. Integrating 
improved access to mental health care with HIV care for 
PLWH has a number of advantages. Firstly, it provides an 
opportunity to manage two commonly co-occurring dis-
orders to provide a patient-centred approach and remove 
the barrier of poor communication between providers for 
the different conditions. Secondly, integration provides 
us with the opportunity to leverage the limited number 
of mental health workers as consultants, to improve the 
capacity of the HIV care delivery platform to address 
mental illness. Lastly, integrated care programs that 
address patients’ mental health needs in the context of a 
regular HIV care service are likely to be more attractive 
to patients and family members who are concerned about 
the stigma that is still associated with mental illness and 
their treatment settings [22, 23].
One of the best described and evaluated integration 
model for mental health is the Collaborative Care (CC) 
model which provides a pragmatic strategy to deliver 
integrated mental health and general medical care in pri-
mary care settings [24]. CC models provide a team-based, 
multicomponent intervention that enacts care delivery 
redesign by systematically improving coordination of 
patient care through organisational leadership support, 
evidence-based provider decision-making, and clini-
cal information systems as well as engaging patients in 
their care through self-management support and linkages 
to community resources [25]. Systematic reviews have 
reported that CC models can be a cost-effective strategy 
for primary care practices to improve mental and physi-
cal outcomes for a range of mental health conditions 
across diverse populations and primary care settings [26, 
27]. A systematic review of the constituents of CC inter-
ventions which predict favourable outcomes reported the 
following components: use of routine screening, the pro-
fessional skills of staff and specialist supervision [28].
There is a growing evidence of the applicability of 
CC models in LMIC, with several studies showing 
Discussion: The study findings will inform policy makers and practitioners on the cost-effectiveness of a stepped 
care approach to integrate depression management in routine care for PLWH in low-resource settings.
Trial registration: ISRCTN, ISRCTN86760765. Registered 07 September 2017, https:// doi. org/ 10. 1186/ ISRCT N8676 0765.
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effectiveness in management of depression and anxi-
ety disorders in primary care settings [29–31]. In these 
models, nurses and lay community health workers were 
employed to provide depression and anxiety manage-
ment including psychotherapies [29–31]. This task-
sharing approach has been shown to encourage effective 
sharing of tasks between medical, specialist and non-
medical staff [32]. Additionally, in the above CC mod-
els, mental health treatment was provided in levels or 
steps (“stepped care”) with the most intensive treatments 
reserved for the most severe cases. CC models that inte-
grate stepped care strategies have been reported to max-
imise the efficient use of scarce resources, especially in 
those public health facilities where case management has 
previously been relatively poor [32].
The depression integration model in the planned trial 
(“HIV + D”) is based on the MANAS intervention [30], a 
stepped CC delivery model that demonstrated effective-
ness for the management of depressive and anxiety dis-
orders delivered by lay health workers in primary health 
care clinics in India. The HIV + D model is based on ther-
apies that have been shown to be effective against DD in 
primary care settings including in HIV care, namely: psy-
choeducation [33], behavioural activation-the Healthy 
Activity Program (HAP) [34] and antidepressant medica-
tions [35, 36].
A similar trial, the CobALT trial is being conducted in 
HIV care in South Africa [37] to evaluate the effective-
ness of mental health integration models in HIV primary 
care. The HIV + D trial differs from the CobALT trial in 
that it is being undertaken in Uganda which has a weaker 
health system than South Africa. In addition, the pro-
posed trial, unlike the CobALT trial, is using an evidence 
based psychotherapeutic treatment (Behavioural Activa-
tion; BA [34].
Developing the HIV + D intervention
We employed robust methodology for intervention 
development [38] using a systematic, phased approach 
with the following phases: (I) formative research to 
inform initial intervention modelling; (II) field testing 
and refinement in pilot evaluations; (III) a definitive ran-
domised controlled trial.
Phases I and II were undertaken in one peri-urban 
district of Mpigi in central Uganda from November 
2017 to February 2020. These involved: (i) adapting the 
MANAS collaborative stepped care intervention and a 
behavioural activation therapy (Health Activity Program-
HAP) to the HIV care situation of Uganda, (ii) conduct-
ing a pilot study to assess feasibility and acceptability 
of the developed HIV + D intervention model and (iii) 
local adaptation and validation of the patient cost ques-
tionnaires and the standardised health and non-health 
quality of life outcome measurement tools (EQ-5D-5 L 
and OxCAP-MH).
To adapt MANAS, we employed the Theory of Change 
(ToC) based approach [39], involving consultation with 
key stakeholders (district health managers and planners, 
health workers involved in HIV care, representatives 
of PLWH, Mental health and HIV non-governmental 
organisations, Ministry of Health representatives from 
the AIDS Control Programme and the Mental Health 
Department, and mental health specialists). Three ToC 
workshops were conducted with stakeholders, result-
ing in a ToC map that specified the causal pathways, the 
required interventions, assumptions and indicators to 
attain the desired impact (improved mental well-being 
among HIV patients). These outputs were used to inform 
and further develop the HIV + D intervention.
The local adaptation of behavioural activation therapy 
(HAP) involved holding consultative meetings with key 
stakeholders that included mental health experts, HIV 
clinicians and counsellors and PLWH in order to iden-
tify locally appropriate supportive strategies to behav-
ioural activation (BA) that were feasible for delivery by 
lay health workers (LHW) and acceptable in the HIV 
care situation of Uganda. The agreed upon supportive 
strategies to BA were: psychoeducation, problem solv-
ing, relaxation, social networks, rumination management 
and sleep management. The HAP manual and counse-
lor’s manual which act as the treatment guide had their 
text simplified and shortened and translated in the local 
Luganda language due to low literacy among LHW.
To evaluate the acceptability and feasibility of the 
HIV + D intervention, a case series of 131 PLWH was 
undertaken over six months at four public health care 
facilities in Mpigi district. PLWH were screened and 
those with a PHQ-9 score ≥ 10 were triaged to the appro-
priate level of depression management in the HIV + D 
intervention model. Enrolled patients were followed over 
6 months, with monthly assessment of their depressive 
symptoms using the PHQ-9. In addition, serial quali-
tative interviews were carried out with clients and lay 
therapists to gain their perspectives on delivery and use 
of the intervention. Findings from this formative work 
were used iteratively to further refine the HIV + D inter-
vention. The developed HIV + D intervention model 
consists of psychoeducation, Behavioural Activation, 
antidepressant medication and referral to mental health 
workers, delivered in a stepped care fashion and on the 
whole, found to be acceptable to the different stakehold-
ers including PLWH.
After the formative work, the BA sessions were 
extended from the original 30–40 min to 45–60 min, due 
to low literacy of both the LHW and study participants; 
changes were also made to the number of sessions (from 
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the original 6 optimum sessions to 4 optimum sessions 
with a range of 4–10 sessions). In addition, the commu-
nity resources section of the HAP was modified to reflect 
the key local psychosocial stressors (need for support to 
orphans and other vulnerable children, domestic violence 
and land disputes).
The objective of the local adaptation and validation 
of the health economics instruments was to evaluate 
the ease of use and understandability of the patient 
cost questionnaire, EQ-5D-5 L and OxCAP-MH tools 
which had been translated from English into Luganda. 
This was achieved through the administration of 
these tools to a random sample of 20 study respond-
ents drawn from the 4 PHCFs participating in the pilot 
study. During administration of the tools, participants 
were encouraged to provide feedback on the Luganda 
terms used, length of the tools and ease of under-
standing of the questions. This feedback was used to 
improve the study tools.
This work showed the feasibility and acceptability of 
the HIV + D model, with preliminary evidence of a clini-
cally meaningful improvement in DD scores.
Aim and hypothesis
The aim of the planned trial is to evaluate effectiveness 
of the HIV + D intervention on depressive disorders, 
functional outcomes and its cost-effectiveness in routine 
HIV care in Uganda. We hypothesise that, among PLWH 
with comorbid DD in Uganda, the HIV + D interven-
tion in addition to EUC will be superior to EUC alone in 
improving clinical and functional DD outcomes, clinical 
symptoms of generalised anxiety disorder, ART adher-
ence, will be cost-effective and will improve uptake and 




The study is a cluster-randomised trial with primary 
endpoint at 3 months’ post-randomisation. It will be 
conducted among 1200 PLWH attending 40 clusters 
(PHCFs) that provide HIV care. To be eligible, ran-
domly selected PHCFs have to offer HIV care and 
treatment services to at least 100 PLWH. Eligible clin-
ics will be selected from the 51 PHCFs in the three 
study districts of Wakiso and Masaka (semi-urban 
and rural) and Kalungu (rural) which in addition to 
treating other medical conditions provide HIV care 
to between 50 and 13,000 PLWH per PHCF depend-
ing on size. Randomisation will be completed by an 
independent statistician using a list of random num-
bers generated by statistical software (Stata 16.1 SE), 
and will be stratified by type of health facility (health 
centres versus hospitals). Within each stratum, clin-
ics will be randomised in a 1:1 ratio to either the Col-
laborative Stepped Care arm (CSC arm; to receive 
EUC plus the HIV + D intervention) or the EUC arm 
(Fig. 1). A minimum of 10 and a maximum of 30 eli-
gible DD positive study participants will be enrolled 
per participating PHCF. The reporting of the trial will 
be in accordance with the SPIRIT guidelines for inter-
ventional trials [40] (Additional file 1: Appendix 1).
Participant eligibility criteria and recruitment
Inclusion criteria
PLWH who have been on ART for at least 6 months, ≥ 18 
years, residing in the study area, medically stable (not 
too ill to require emergency admission) at the time of the 
study, conversant in English or Luganda (the predomi-
nantly used local language), willing to be home visited (in 
instances of loss to follow up) and able to give informed 
consent will be eligible for enrollment if they score ≥ 10 
on the PHQ-9.
Exclusion criteria
Potential participants who meet the above inclusion 
criteria but have impairments that hinder engagement 
with the research procedures for any reason (e.g. is deaf 
or hard of hearing, speech impaired, blind or partially 
sighted), unable to give informed consent, are already 
receiving treatment for depression or any psychiatric 
treatment before the trial and those with alcohol use 
problem will be excluded.
Recruitment
A health talk about depression will be given by the 
LHW to PLWH sitting in the triage area of the partici-
pating PHCFs. Thereafter, consecutive attenders will 
be approached and requested to be screened for the 
study until the day’s target is reached (4–5 PLWH who 
have a PHQ-9 score of ≥ 10), screening will be under-
taken by the LHW. Selected study respondents will 
be screened for depression using the PHQ-2, a two-
item questionnaire that assess for ‘depressed mood’ 
and ‘loss of interest in typically pleasurable activities’. 
Those who screen positive (PHQ-2 score ≥ 3) will be 
invited for further evaluation by the LHW for trial eli-
gibility and consent. Eligibility assessment will include 
confirmation of DD using the PHQ-9 [41]. Eligible 
respondents with suicidal ideation (endorsing item 
9 on the PHQ-9) once enrolled will immediately be 
referred to supervisor for further assessment using 
MINI to determine suicidality level. Supervisor will 
consult with or refer to mental health worker for fur-
ther management plan.
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Blinding
By design, there is no way to blind the participants on 
whether or not they receive the intervention. However, 
the outcome assessors will be blinded to which partici-
pants are in the intervention or control group.
Health care facilities providing HIV care in study districts of Wakiso, Masaka, Kalungu (Health 
Centre III, IV and Hospitals (N=74)
PHCFs eligible (n= 51) 
Randomization of PHCFs (n=40) 
PHCFs allocated to CSC (n=20) 
Participants to receive CSC (n=600 
PLWH)  
 PHCFs received CSC (n=) 
 Participants received CSC (n=) 
 PHCFs didn’t receive CSC (n=), 
(reasons) 
 Participants didn’t receive CSC (n=), 
(reasons) 
PHCFs allocated to EUC (n=20) 
Participants to receive EUC (n=600 
PLWH) 
 PHCFs received EUC (n=) 
 Participants received EUC (n=) 
 PHCFs didn’t receive EUC (n=), 
(reasons) 
 Participants didn’t receive EUC (n=), 
(reasons) 
Follow-up data to be collected at; 3 
and 12 months’ post-enrolment 
Lost to follow-up (n= No of lost to 
follow-up participants) (reasons) 
Discontinued from study (n= No of 
discontinued participants) (reasons)
Follow-up data to be collected at; 3 
and 12 months’ post-enrolment 
Lost to follow-up (n= No of lost to 
follow-up participants) (reasons) 
Discontinued from study (n= No of 
discontinued participants) (reasons)
Excluded (n= 23) (private health facilities)    
PHCFs analysed (n=) 
Participants analysed (n=) 
PHCFs excluded from analysis (n=) 
(reasons) 
Participants excluded from analysis 
(n=) (reasons) 
PHCFs analysed (n=) 
Participants analysed (n=) 
PHCFs excluded from analysis (n=) 
(reasons) 





















Excluded (n= 11) (random selection)             
Fig. 1 HIV + D Trial flow-chart: PHCFs Public Health Care Facilities, PLWH People Living with HIV, CSC Collaborative Stepped Care, EUC Enhanced 
Usual Care
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Interventions
All participants in the trial will receive Enhanced Usual 
Care. Usual mental health care in the HIV care situa-
tion of Uganda and many other sub-Saharan African 
settings, is effectively no mental health care. This is 
primarily because DD is not routinely assessed for 
or diagnosed. In this study, enhanced usual care will 
be provided-defined by (i) providing the DD screen-
ing results to the attending clinician and (ii) providing 
mhGAP training to attending clinicians for the target 
disorders including guidelines on when and where to 
refer patients for psychiatric care.
In addition to EUC, providers in the intervention arm 
clinics will receive training in mhGAP and the HIV + D 
intervention. The HIV + D intervention will consist 
of evidence-based treatments for depression (psych-
oeducation, behavioural activation and antidepres-
sant medications) delivered in a stepped care format 
and overseen by an HIV counsellor/case manager. The 
HIV + D intervention will be delivered in 4 steps. Step 
1: (initiation of treatment), patients with PHQ-9 scores 
of 10–19 are told of their scores and offered psychoe-
ducation by a LHW. Step 2: (management of moder-
ate to severe cases), patients who remain symptomatic 
at follow up (PHQ-9 score ≥ 5 after 4 weeks) will be 
offered BA; 4–10 sessions) by a LHW. Step 3: (monitor-
ing outcomes), if after 6 sessions of BA, PHQ-9 scores 
are ≥ 10, the advice is to continue BA sessions to com-
pletion and add antidepressant medication (Fluoxetine 
20 mg/day for 6 months), initiated by the HIV clinician. 
Step 4: (referral to mental health worker), if there is no 
improvement (PHQ-9 ≥ 5) after step 3 or at eligibil-
ity assessment PHQ-9 ≥ 20, or if someone has a high 
suicide risk (based on suicide risk assessment using 
the suicidality module of the Mini International Neu-
ropsychiatric Interview (MINI) [42] by the supervisor 
for those who score ≥ 1 on item 9 of the PHQ-9 which 
reads, ‘over the last 2 weeks, how often have you had 
thoughts that you would be better off dead or of hurt-
ing yourself in some way?), continue all existing treat-
ment and refer to a mental health worker.
To recruit LHW for this study, a local advert will be 
run at each of the participating PHCF. Minimum qualifi-
cations will include at least 11 years of formal education 
and a certificate of good conduct from the Local Coun-
cil I (LC I) leadership, previous training and work in a 
counsellor role will be an added advantage. Training of 
LHW will employ both didactic methods and the use of 
role plays. Supervision of LHWs will be undertaken by 
the supervising HIV counsellor including through weekly 
supervision meetings where samples of audio-recordings 
of the therapy sessions will be listened to and feedback 
provided.
Fidelity to the intervention
To ensure fidelity in the delivery of the treatment by 
LHW, the BA therapy sessions have been manualised 
and all therapy sessions with clients will be audio-
recorded. A random sample of these recordings will be 
discussed with the case manager at weekly clinic meet-
ings. Quantity and quality level fidelity indicators of 
the treatment will be collected and evaluated. Quantity 
indicators will be obtained from the study participants’ 
case records where the types of treatment offered, 
number of sessions per treatment provided and dura-
tion of treatment sessions, will be routinely collected 
by standardised questionnaire. Quality indicators 
will be assessed through ratings of 10 % of the audio-
recording of all sessions by independent assessors blind 
to outcome data using standardised quality assessment 
questionnaires.
Treatment monitoring and discharge from treatment
The recruited study participants will be followed for 12 
months’ post-randomisation. The monitoring schedule 
in the intervention arm will include assessment at 4, 16 
and 40 weeks respectively. At these assessment points, 
the intervention team (LHW and their supervisors) will 
decide whether the patient should be considered for 
discharge (PHQ-9 < 5) or stepped up to the next level of 
care. Patients will be discharged from treatment if their 
PHQ-9 scores remain below 5 at a follow-up review 4 
weeks after a scheduled monitoring visit. Participants 
with a high suicide risk at any assessment point will be 
referred to the mental health worker.
Study outcomes measures
The study outcome measures will be collected by means 
of questionnaires that will be administered to study 
participants by trained research assistants (TRA) who 
will be separate from the study implementation team. 
Data collection by TRA will be supported and overseen 
by Research Supervisors (RS; trained psychiatric nurses 
or psychiatric clinical officers who will each oversee 
four study PHCFs). The three-month outcome is the 
primary end-point of the trial as majority of study par-
ticipants will have completed their BA sessions and we 
would expect the optimal effect of the treatment. The 
12-month end-point is included to evaluate the sustain-
ability of the effect of the intervention. The outcome 
assessment measures with the specific outcomes are 
summarised in Table 1. The primary outcome measure 
in this study will be the mean DD symptom severity 
scores (assessed using the PHQ-9) at 3 months.
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Sample size and power considerations
Power considerations for primary outcome
Twenty clusters will be randomized to each study arm, 
with the randomisation stratified by type of health facil-
ity. The sample size for this trial was calculated using the 
following assumptions, with testing carried out at the 
2.5 % significance level for the primary endpoint to allow 
for multiple testing:
a. For the mean DD symptom severity score at 3 
months.
1. The within-cluster standard deviation in both arms 
for the DD combined symptom severity score will 
be at most 4.4 units (based on the results of the 
INDEPTH trial in Uganda [43], for screen positive 
subjects).
2. The mean symptom severity score in the CSC arm at 
3 months will be 4 units compared to a mean score of 
6 units in the EUC arm.
3. The harmonic mean of the number of participants 
per clinic will be 15.
4. The between cluster coefficient of variation for the 
PHQ-9 score will be 0.25 in both arms.
Using these assumptions and the formula from Hayes 
and Moulton [44] (page 110 Eq. 7.9) C = 1 + (zα/2 + zβ)2 
{2 σw2 / m + k2 (µ02 + µ1 / (µ0−µ1) [44]; where m is the 
harmonic mean of the number of participants per clinic, 
k is the between cluster coefficient of variation, σw2 is 
the within-cluster variance of the DD combined symp-
tom severity scores, µ0 is the mean DD combined symp-
tom severity score at 3 months in the EUC arm and µ1 
the combined symptom severity score at 3 months in the 
CSC arm.
Then a sample size of 20 clusters per arm will give 90 % 
power to detect as statistically significant at the 2.5 % 
level a true mean difference between the EUC and CSC 
arms of 2 units in the DD symptom severity score.
The sample size calculation is conservative in having 
used a large estimate of the within cluster standard devia-
tion, as adjusting for baseline DD score is likely to reduce 
this.
Data collection and management
Data from study participants at baseline, 3 months, and 
12 months’ post-enrollment will be collected on printed 
interviewer-administered face-to-face paper question-
naires which will be stored in lockable filing cabinets at 
each study site. All the completed questionnaires will be 
reviewed by a research team member for missing data 
and unusual responses. Corrective action will be under-
taken where necessary by the study research assistant, 
either by means of a telephone call or by asking the study 
participant to come back to the clinic. For this, the Data 
Table 1 HIV + D outcome measures and specific outcomes
Key: Carer = lay health worker, case manager, mental health workers; ART  antiretroviral therapy








 Mean DD symptom severity scores PHQ-9 [41] √
Secondary outcomes 
 Mean DD symptom severity scores PHQ-9 [41] √
 Remission (proportion with PHQ-9 scores < 5) PHQ-9 [41] √ √
 Mean generalised anxiety disorder (GAD) severity scores GAD-7 [47] √ √
 Quality adjusted life years (QALYs) EQ-5D-5 L [48] √ √
 Days out of work (over 3 months) Patient cost questionnaire √ √
 Functional impairment and welfare OxCAP-MH [49] √ √
 Patients’ satisfaction with depression care Modified Patient Satisfaction Survey by Ede et al. [50] √
 Carers’ perceptions and satisfaction levels with integration 
efforts at HIV clinic
Modified Staff Survey by Ede et al.  [50] √
 Proportion with virological failure (a proxy measure of adher-
ence; defined as a viral load of 400 copies/ml or more)
HIV viral load (copies/ml) √
 Reported adherence to ART (proportion of participants who 
have missed at least one dose of ART in the past three days 
compared against the baseline value)
Assessed by means of the question, ‘Have you missed 
taking ART in the last 3 days?’ Possible responses 1 = Yes, 
2 = No
√ √
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Section of the MRC/UVRI & LSHTM Uganda Research 
Unit will design a study database in OpenClinica, using 
unique study identification-number as a linking field. At 
regular intervals study questionnaires will be retrieved 
and transferred to the data section of the MRC/UVRI 
& LSHTM Uganda Research Unit for double data entry. 
During data entry, the data manager will periodically 
carry out a set of pre-defined quality checks on the data 
and raise any queries with the research assistants through 
the study coordinator. The OpenClinica database will 
maintain a complete audit trail of the changes made dur-
ing data cleaning. Once data for a given survey round in 
the cluster randomised trial has been cleaned and vali-
dated, the data will be locked and exported to Stata for 
statistical analysis. The dedicated data manager assigned 
to the study will carry out regular quality control checks 
on the study database. When all of the queries of a given 
phase of the study, or a given round of the cluster rand-
omized trial have been addressed, the data manager will 
upload the cleaned data into the main study database. 
The main study database will be backed up onto a secure 
location using a mirror server. In addition, the data man-
ager will maintain a password protected copy of the data-
base on his/her computer and on an external hard drive. 
A detailed data dictionary will be prepared to help with 
the curation of the data. The master database for the 
study will be maintained on the server of the Unit. The 
data manager and study statisticians will also have pass-
word protected copies of the master database.
Statistical analysis
Analyses will be conducted on an intention-to-treat 
(ITT) basis. For the primary outcome of ‘DD symptom 
severity scores at 3 months’ linear mixed models will 
be fitted to compare the two treatment arms (CSC and 
EUC) with terms for treatment arm, stratum (level of 
health facility) and baseline DD symptom severity score, 
with a random effect fitted for clinic. A priori moderators 
will include gender, social class and baseline severity.
For the binary secondary outcome measures, random 
effects logistic regression models will be fitted with simi-
lar terms to those fitted for the DD severity score analy-
sis. Models with multiple time periods will be estimated 
using ANCOVA assuming low auto-correlation between 
time periods [45]. Exploratory longitudinal analyses will 
be carried out using three-level multilevel models with 
the levels being clusters, PLWH within clusters and occa-
sions within PLWH (periods). These models will con-
sider (a) the effect of period e.g. whether the symptom 
score decreases linearly over time and (b) whether there 
is a treatment arm by period interaction i.e. whether the 
treatment effect reduces or increases over time.
For the cost-effectiveness component of the study, 
a micro-costing will be performed to obtain the mean 
cost per patient, the EQ-5D will be used to construct 
QALYs and a Markov model will be used to predict the 
outcomes and cost over the lifetime of the patients [45].
Missing data on outcomes and key covariates will be 
assessed, and if > 5 % of participants are missing data 
multiple imputation methods appropriate for multilevel 
data will be used [46].
Monitoring the trial
Four committees will monitor the progress of the 
trial, that is, Independent Data Monitoring Commit-
tee (IDMC), Trial Steering Committee (TSC), Trial 
Management Team (TMT) and the Trial Management 
Group (TMG) and details are shown in Additional 
file 2: Appendix 2.
Ethics and dissemination
The protocol was reviewed and approved by the Uganda 
Virus Research Institute (UVRI) Research and Ethics 
Committee (reference number GC/127/20/04/772), the 
Uganda National Council for Science and Technology 
(reference number HS645ES), and the London School 
of Hygiene and Tropical Medicine (LSHTM) Ethics 
Committee (reference number 22,567). Any protocol 
modifications will be submitted to the UVRI Research 
and Ethics Committee for review, and participants will 
be informed if warranted. The LSHTM is the trial spon-
sor. Written (or witnessed if the participant is illiterate) 
informed consent will be mandatory to enrolment. All 
participant data will be stored securely and access will 
be restricted. In order to maintain participant confi-
dentiality, all study data collection forms will only be 
identified by the study identification numbers. Docu-
ments that contain participant’s names such informed 
consent forms will be stored separately from data col-
lection forms. All databases will be password protected. 
HIV-infected persons who do not enrol in the study 
for any reason will be counselled and referred for care. 
Serious Adverse Events (SAEs) (death, suicide attempt, 
hospitalisation) from any cause will be reported as soon 
as possible within seven calendar days of becoming 
aware of SAE to the UVRI Research and Ethics Com-
mittee and to the IDMC.
Results produced by this investigation will be presented 
at local and international conferences and published in a 
timely fashion, ideally in the last year of the study period. 
All final peer-reviewed manuscripts that arise from this 
proposal will be submitted to the digital archive PubMed 
Central for open access.
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Discussion
The aim of the HIV + D trial is to provide evidence on 
the effectiveness and cost-effectiveness of a scalable 
model for the integration of depression management in 
HIV care in public health facilities in low resourced set-
tings such as those in Uganda. This intervention model 
aims to reduce the treatment gap posed by the growing 
burden of depression among adult persons living with 
HIV in settings where they currently have no mental 
health care and where there is an acute shortage of men-
tal health professionals. This project is responding to the 
Ministry of Health which for the first time in 30 years of 
the HIV epidemic in Uganda has called for the manage-
ment of depression in the national HIV prevention and 
treatment guidelines [15]. These guidelines specifically 
called for an integrative approach to the management of 
HIV related comorbidities such as depression [15]. The 
HIV + D Trial is testing the effectiveness of a health sys-
tems intervention based on the MANAS intervention 
that demonstrated effectiveness for the management 
of depressive and anxiety disorders in primary care set-
tings in India [30]. A variation of this model, the CobALT 
trial is currently underway in South Africa [37]. The col-
laborative care model being evaluated in this trial will 
be led by lay health care workers under the supervision 
of HIV care counsellors (general nurses trained in HIV 
counselling) and supported by mental health workers 
using a manualised behavioural activation based ther-
apy (the Health Activity Program). The trial design is a 
cluster randomised trial conducted in 40 HIV care clin-
ics in public health care facilities across three districts in 
central and south-western Uganda. The study outcomes 
will be measured on 1200 adult persons living with HIV 
who have screened positive for depression. It will pro-
vide evidence of the effectiveness and cost effectiveness 
of the intervention on mental, physical and health system 
outcomes and will highlight the benefits of attending to 
mental disorders in HIV care programming. Dissemina-
tion activities will be organised to share the findings from 
the cluster randomised trial with stakeholders. An appli-
cation for further funding will be made to scale up the 
model if found to be effective.
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